Background
In many low-income countries, households bear most of the health care costs. Community-based health insurance (CBHI) schemes have multiplied since the 1990s in West Africa. They have significantly improved their members’ access to health care. However, a large proportion of users are reluctant to subscribe to a local CBHI. Identifying the major factors affecting membership will be useful for improving CBHI coverage. The objective of this research is to obtain a general overview of existing evidence on the determinants of CBHI membership in West Africa.
Methods
A review of studies reporting on the factors determining membership in CBHI schemes in West Africa was conducted using guidelines developed by the Joanna Briggs Institute. Several databases were searched (PubMed, ScienceDirect, Global Health database, Embase, EconLit, Cairn.info, BDPS, Cochrane database and Google Scholar) for relevant articles available by August 15, 2022, with no methodological or linguistic restrictions in electronic databases and grey literature.
Results
The initial literature search resulted in 1611 studies, and 10 studies were identified by other sources. After eliminating duplicates, we reviewed the titles of the remaining 1275 studies and excluded 1080 irrelevant studies based on title and 124 studies based on abstracts. Of the 71 full texts assessed for eligibility, 32 additional papers were excluded (not relevant, outside West Africa, poorly described results) and finally 39 studies were included in the synthesis. Factors that negatively affect CBHI membership include advanced age, low education, low household income, poor quality of care, lack of trust in providers and remoteness, rules considered too strict or inappropriate, low trust in administrators and inadequate information campaign.
Conclusions
This study shows many lessons to be learned from a variety of countries and initiatives that could make CBHI an effective tool for increasing access to quality health care in order to achieve universal health coverage. Coverage through CBHI schemes could be improved through communication, improved education and targeted financial support.
Rheumatoid arthritis (RA) is the most common auto-immune disease. Rarely described in Niger, we reported its epidemiological, clinical, paraclinical, therapeutic, and evolutionary aspects in hospitals environments. In order to analyze these aspects in detail, a prospective study has been realized over a period of one (1) year in the Rheumatology Department of the Regional Hospital Center of Maradi. We have included all RA cases in accordance with the ACR/EULAR classification criteria of 2010. The data was entered and analyzed on SPSS 20.0 software. After collecting and studying 32 AR observations from among 846 rheumatologic consultations, the results have demonstrated different points: the average patient's age is 38,9 years, the delay for the diagnosis was 6 years, and in some cases extraarticular manifestations have been observed. The results show that the inflammatory syndrome was constant and that the treatment remains classic with non-pharmacologic means, analgesics, NSAID (non-steroidal antiinflammatory agent), infiltrations and DMARDs (disease-modifying anti-rheumatic drug). The evolution is positive in all the cases. Thanks to this study it is possible to affirm that rheumatoid arthritis is a reality in Niger and it has been better described. The diagnosis is late, the articular and systemic manifestations are the same as in Caucasians, but the autoimmunity seems less. The disease is very active, altering the quality of life. As for its treatment, conventional background therapy still remains effective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.